{
    "clinical_study": {
        "@rank": "151463", 
        "arm_group": [
            {
                "arm_group_label": "Mepolizumab 300 mg", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this randomized, double-blind study is to investigate the efficacy and safety\n      of mepolizumab (300 milligram [mg] administered subcutaneously [SC] every 4 weeks) compared\n      with placebo over a 52-week study treatment period in subjects with relapsing or refractory\n      Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care therapy\n      including background corticosteroid therapy with or without immunosuppressive therapy.\n      During the treatment period, in accordance with standard of care, corticosteroid dose will\n      be tapered. The key outcomes in the study focus on evaluation of clinical remission, defined\n      as Birmingham Vasculitis Activity Score (BVAS)=0 with a corticosteroid dose of <=4 mg/day\n      prednisolone/prednisone, reduction in disease relapse and reduction in corticosteroid\n      requirement."
        }, 
        "brief_title": "A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Churg-Strauss Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Churg-Strauss Syndrome", 
                "Wegener Granulomatosis", 
                "Systemic Vasculitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed Consent:  Able to give written informed consent prior to participation in\n             the study, which will include the ability to comply with the requirements and\n             restrictions listed in the consent form.  Subjects must be able to read, comprehend,\n             and write at a level sufficient to complete study related materials.\n\n          -  Age and gender: Male or female subjects age 18 years or older.\n\n          -  EGPA diagnosis: subjects who have been diagnosed with EGPA for at least 6 months\n             based on the history or presence of: asthma plus eosinophilia (>1.0x10^9/Liter and/or\n             >10% of leucocytes) plus at least two of the following additional features of EGPA; a\n             biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular\n             eosinophilic infiltration, or  eosinophil-rich granulomatous inflammation;\n             neuropathy, mono or poly (motor deficit or nerve conduction abnormality); pulmonary\n             infiltrates, non-fixed; sino-nasal abnormality; cardiomyopathy (established by\n             echocardiography or Magnetic Resonance Imaging); glomerulonephritis (haematuria, red\n             cell casts, proteinuria); alveolar haemorrhage (by bronchoalveolar lavage); palpable\n             purpura; anti neutrophil cytoplasmic anti-body (ANCA) positive (Myeloperoxidase or\n             proteinease 3).\n\n          -  History of relapsing OR refractory disease defined as: Relapsing disease:\n\n        Subject must have a past history of at least one confirmed EGPA relapse (i.e., requiring\n        increase in oral corticosteroids (OCS) dose, initiation/increased dose of\n        immunosuppressive therapy or hospitalisation) within the past 2 years which occurred at\n        least 12 weeks prior to Screening (Visit 1) whilst receiving a dose of prednisolone (or\n        equivalent) of >=7.5 milligram per day (mg/day). Refractory disease: Either: Failure to\n        attain remission (BVAS=0 and OCS dose <=7.5 mg/day prednisolone or equivalent) within the\n        last 6 months following induction treatment with a standard regimen, administered for at\n        least 3 months. Note: a) Subjects who have received a cyclophosphamide (CYC) induction\n        regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3\n        weeks after the last dose of pulsed intravenous CYC prior to Baseline (Visit 2), if their\n        total white blood cells (WBC) is >=4x10^9/Liter (tested at the local laboratory, if\n        necessary) prior to randomisation. b) Subjects who have received a methotrexate,\n        azathioprine, or mycophenolate mofetil induction regimen may be included if on a stable\n        dose for at least 4 weeks prior to Baseline (Visit 2). c) Subjects who have received an\n        induction regimen comprising corticosteroids alone may be included only if they have\n        failed to attain remission after 3 months of treatment AND the corticosteroid dose is >=15\n        mg/day prednisolone or equivalent for the 4 weeks prior to Baseline (Visit 2). Or: Within\n        6 months prior to Screening (Visit 1), recurrence of symptoms of EGPA (not necessarily\n        meeting the protocol definition of relapse) whilst tapering OCS, occurring at any dose\n        level >=7.5 mg/day prednisolone or equivalent.\n\n          -  Corticosteroid therapy: Subject must be on a stable dose of oral prednisolone or\n             prednisone of >=7.5 mg/day (but not >50 mg/day) for at least 4 weeks prior to\n             Baseline (Visit 2).\n\n          -  Immunosuppressive therapy: If receiving immunosuppressive therapy (excluding\n             cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit\n             2) and during the study (dose reductions for safety reasons will be permitted).\n\n          -  ECG measurements: QTc(F)<450 msec or QTc(F)<480 msec for patients with bundle branch\n             block. The QTc is the QT interval corrected for heart rate according to either\n             Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or\n             manual overread. For subject eligibility and withdrawal decisions, QTcFwill be used.\n             For purposes of data analysis, QTcF will be used as primary though data using both\n             correction formulas will be collected and analysed. The QTc should be based on single\n             or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief\n             recording period.\n\n          -  Female subjects: To be eligible for entry into the study, females of childbearing\n             potential (FCBP) must commit to consistent and correct use of an acceptable method of\n             birth control (as discussed in the protocol) beginning with consent, for the duration\n             of the trial and for 4 months after the last study drug administration.\n\n          -  French subjects: In France, a subject will be eligible for inclusion in this study\n             only if either affiliated to or a beneficiary of a social security category.\n\n        Exclusion Criteria:\n\n          -  GPA or MPA: Diagnosed with granulomatosis with polyangiitis (GPA; previously known as\n             Wegener's granulomatosis) or microscopic polyangiitis (MPA).\n\n          -  Organ-threatening EGPA: Organ-threatening EGPA as per European league against\n             rheumatism (EULAR) criteria, i.e., organ failure due to active vasculitis, creatinine\n             >5.8 gram per deciliter (g/dL) (>513 micromole per liter [\u00b5mol/L]) within 3 months\n             prior to Screening (Visit 1).\n\n          -  Life-threatening EGPA: Imminently life-threatening EGPA disease defined as any of the\n             following within 3 months prior to Screening (Visit 1); Intensive care required;\n             Severe alveolar haemorrhage or haemoptysis requiring transfusion or ventilation or\n             haemoglobin < 8 gram per liter (g/dL) (<80 g/L) or drop in haemoglobin > 2 g/dL (>20\n             g/L) over a 48 hour period due to alveolar haemorrhage; Rapidly progressive\n             glomerulonephritis (RPGN) with creatinine > 2.5 milligram per deciliter (mg/dL) (>221\n             \u00b5mol/L) or rise in creatinine > 2 mg/dL (>177 \u00b5mol/L) over a 48 hour period; Severe\n             gastrointestinal (GI) involvement, e.g., gangrene, bleeding requiring surgery; Severe\n             central nervous system (CNS) involvement; Severe cardiac involvement, e.g.,\n             life-threatening arrhythmia, cardiac failure: ejection fraction < 20%, New York Heart\n             Association Class III/IV (as discussed in protocol), acute myocardial infarction.\n\n          -  Malignancy: A current malignancy or previous history of cancer in remission for less\n             than 12 months prior screening (Subjects that had localized carcinoma (i.e., basal or\n             squamous cell) of the skin which was resected for cure will not be excluded).\n\n          -  Liver disease: Unstable liver disease (as defined by the presence of ascites,\n             encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or\n             persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception\n             of Gilbert's syndrome or asymptomatic gallstones).\n\n          -  Cardiovascular: Subjects who have severe or clinically significant cardiovascular\n             disease uncontrolled with standard treatment including but not limited to: Known\n             ejection fraction of <30%,  OR Severe heart failure that meets New York Heart\n             Association Class IV  (as discussed in protocol), OR Hospitalised in the 12 months\n             prior to Visit 1 for severe heart failure meeting New York Heart Association Class\n             III (as discussed in protocol), OR Angina diagnosed less than 3 months prior to or at\n             Visit 1 (Screening).\n\n          -  Other concurrent medical conditions: Subjects who have known, pre-existing,\n             clinically significant endocrine, autoimmune, metabolic, neurological, renal,\n             gastrointestinal, hepatic, haematological, respiratory or any other system\n             abnormalities that are not associated with EGPA and are uncontrolled with standard\n             treatment.\n\n          -  Infectious disease: Chronic or ongoing active infectious disease requiring systemic\n             treatment.\n\n          -  Parasitic infection: Subjects with a parasitic infestation within 6 months prior to\n             Screening (Visit 1).\n\n          -  Hepatitis status: Diagnosis of chronic hepatitis B, as evidenced by positive\n             Hepatitis B surface antigen (HBsAg) at Screening (Visit 1). Japan only: Subjects\n             positive for HBsAg , antibodies to HBsAg, i.e., HBsAb, or Hepatitis B core antigen,\n             i.e., HBcAb, at Screening (Visit 1). Note: Subjects with antibodies to HBsAg, i.e.,\n             HBsAb positive, only (i.e., negative for HBsAg and HBcAb) with a history of hepatitis\n             B vaccination can be included.\n\n          -  HIV: Subjects with a known human immunodeficiency virus infection.\n\n          -  Hypersensitivity: Subjects with a known allergy or intolerance to a monoclonal\n             antibody or biologic therapy.\n\n          -  Previous mepolizumab: Subjects who have previously received mepolizumab within a 1\n             year period prior to Screening (Visit 1).\n\n          -  Prohibited medications: Subjects receiving any of the following: OCS: Subject\n             requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the\n             4-week period prior to Baseline (Visit 2); Intravenous or SC corticosteroids in the\n             4-week period prior to Baseline (Visit 2); Omalizumab within 130 days prior to\n             Screening (Visit 1); Cyclophosphamide:  oral CYC within 2 weeks prior to Baseline\n             (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total WBC\n             is >=4x10^9/Liter (measured using the local laboratory if necessary); Rituximab\n             within 12 months prior to Screening (Visit 1); in addition, the subject must have\n             shown recovery of peripheral B-cell count to within the normal range; IV or SC\n             immunoglobulin within 6 months prior to Screening (Visit 1); Interferon-\u03b1 within 6\n             months prior to Screening (Visit 1); Anti-TNF therapy within 12 weeks prior to\n             Screening (Visit 1); Anti-CD52 (alemtuzumab) within 6 months prior to Screening\n             (Visit 1).\n\n          -  Liver Function Tests: obtained at Screening (Visit 1): ALT<2x ULN (upper limit of\n             normal) or if subject is on background methotrexate or azathioprine <3x ULN;  AST<2x\n             ULN or if subject is on background methotrexate or azathioprine   <3x ULN; Alkaline\n             Phosphatase \u22642.0x ULN;Bilirubin \u2264 1.5x ULN (isolated bilirubin>1.5x ULN is acceptable\n             if bilirubin is fractionated and direct bilirubin <35%)\n\n          -  Other laboratory parameter exclusions: Creatinine > 2.5 mg/dL (221 \u00b5mol/L); WBC < 4\n             x10^9/Liter, Platelet count <120,000/millimetre cube (mm^3), Haemoglobin <8 g/dL (<80\n             g/L)\n\n          -  Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be\n             enrolled if they plan to become pregnant during the time of study participation.\n\n          -  Alcohol/substance abuse: A history (or suspected history) of alcohol misuse or\n             substance abuse within 2 years prior to Screening (Visit 1).\n\n          -  Other investigational product: Subjects who have received treatment with an\n             investigational drug within the past 30 days or 5 terminal phase half-lives of the\n             drug whichever is longer, prior to Screening (Visit 1) (this also includes\n             investigational formulations of marketed products).\n\n          -  Other clinical study: Subject is currently participating in any other interventional\n             clinical study.\n\n          -  Adherence: Subjects who have known evidence of lack of adherence to controller\n             medications and/or ability to follow physician's recommendations.\n\n          -  French subjects: the French subject has participated in any study using an\n             investigational drug during the previous 30 days or 5 half-lives (whichever is\n             longer)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020889", 
            "org_study_id": "115921"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mepolizumab 300 mg", 
                "description": "Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.", 
                "intervention_name": "Mepolizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be available as 0.9% sodium chloride", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "eosinophils", 
            "SB 240563", 
            "Churg-Strauss Syndrome", 
            "quality of life", 
            "mepolizumab", 
            "safety", 
            "biomarkers", 
            "efficacy", 
            "corticosteroids", 
            "Eosinophilic granulomatosis with polyangiitis"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80206"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8N 4A6"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 3L9"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Bron Cedex", 
                        "country": "France", 
                        "zip": "69677"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille cedex 20", 
                        "country": "France", 
                        "zip": "13915"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier cedex 5", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75014"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Suresnes", 
                        "country": "France", 
                        "zip": "92151"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "79106"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Plochingen", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "73207"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fulda", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "36043"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Bramstedt", 
                        "country": "Germany", 
                        "state": "Schleswig-Holstein", 
                        "zip": "24576"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Jena", 
                        "country": "Germany", 
                        "state": "Thueringen", 
                        "zip": "07747"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22767"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "Lombardia", 
                        "zip": "20132"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "Lombardia", 
                        "zip": "20162"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "Toscana", 
                        "zip": "50134"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "Toscana", 
                        "zip": "56126"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan", 
                        "zip": "980-8574"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB2 2QQ"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom", 
                        "zip": "LE3 9QP"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Portsmouth", 
                        "country": "United Kingdom", 
                        "zip": "PO6 3LY"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "France", 
                "Germany", 
                "Italy", 
                "Japan", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Italy: Agenzia Italiana del Farmaco", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Belgium: Belgian Federal Agency for Medicinal and Health Products", 
                "Germany: Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Spain: Spanish Agency for Medicines and Health Products", 
                "Canada: Health Canada", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The accrued number of weeks where BVAS=0 plus prednisolone/prednisone dose <=4 mg/day over the 52 week study treatment period reported as proportion of subjects achieving remission in the following categories: Zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks, >=36 weeks", 
                "measure": "Total accrued duration of remission", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 52"
            }, 
            {
                "description": "Remission is defined as BVAS=0 and prednisolone/prednisone dose <=4 mg/day", 
                "measure": "The proportion of subjects who are in remission at both Weeks 36 and 48 of the study treatment period", 
                "safety_issue": "No", 
                "time_frame": "Weeks 36 and 48"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "EGPA relapse is defined as worsening or persistence of active disease characterised by active vasculitis (BVAS >0) or active asthma symptoms and/or signs with a corresponding worsening in Asthma Control Questionnaire (ACQ) 6 score or active nasal and/or sinus disease with a corresponding worsening in at least one of the sino-nasal symptom questions warranting an increased dose of OCS therapy or an increased dose or addition of immunosuppressive therapy or hospitalisation related to EGPA worsening", 
                "measure": "Time to first confirmed EGPA relapse", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }, 
            {
                "measure": "The proportion of subjects with an average daily prednisolone/prednisone dose of 0 mg, >0 to <=4.0 mg, >4.0 to <=7.5 mg and >7.5 mg during the last 4 weeks of the study treatment period (48 through 52)", 
                "safety_issue": "No", 
                "time_frame": "Week 48 to Week 52"
            }, 
            {
                "measure": "The proportion of subjects in each treatment group who achieve remission (BVAS=0 and prednisolone/prednisone dose <=4 mg/day) within the first 24 weeks of the study and then remain in remission for the remainder of the study treatment period", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "collaborator": {
                "agency": "United States: National Institute of Health; National Institute of Allergy and Infectious Diseases  (NIAID) division", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}